EDMONTON, Dec. 29 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced the closing of a $1.3 million financing. The financing comprised investment of up to $800,000 by AVAC Ltd and $502,700 from the private placement announced on November 14, 2005. Reporting insiders participated in 24.62% of the private placement. Dr. Mark Redmond, Ceapro's President and CEO stated, "This is an important financing for Ceapro. The proceeds will be used for the marketing of CeaProve(TM), Ceapro's diabetes screening, diagnosis, and monitoring test, as well as for general corporate sales and marketing activities. During 2005, we have markedly increased our product sales and at the end of the third quarter reported growth of 25%. This trend has continued in the fourth quarter. This financing will enable us to focus on our growth strategy for 2006." The AVAC investment agreement is for an approved investment of up to $800,000 for CeaProve(TM), Ceapro's diabetes screening, diagnostic, and monitoring product. AVAC's investment will enable Ceapro to further commercialize CeaProve(TM). Previous AVAC investments enabled Ceapro to successfully develop and commercialize a series of products including the active ingredients beta glucan and colloidal oat extracts, as well as product line extensions to the veterinary therapeutic product range. The private placement resulted in the sale of 914 units for a total of $502,700. Each unit consists of 100 common shares priced at $0.50 per share, 100 common share purchase warrants, and 100 royalty interest units at $5.00 per unit. Each warrant entitles the holder thereof to acquire one additional common share at a price of $0.55 per share for a period of six months until June 28, 2006 and thereafter at a price of $0.75 per share until December 28, 2007. The common shares issued under the private placement or upon exercise of the warrants will be subject to a hold period which will expire upon April 29, 2006. Each royalty interest unit entitles the holder to a royalty equal to 0.000025% of the net proceeds received by Ceapro from the sale or license of its Active Ingredients, Animal Health Products and CeaProve(TM) up to a maximum cumulative amount equal to $10.00 per royalty interest unit. About Ceapro Inc. Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources. Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing Companies for 2004 and 2005 and is one of Profit Magazine's Next 100 Companies. Ceapro is also the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro's shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 36,768,593. Closing price December 28, 2005: $0.265 The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward- looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro successfully closes $1.3 million financing
Earlier from Ceapro
- Ceapro announces 2005 third quarter financial results
- Ceapro to present CeaProve(TM) at Canadian Diabetes Association conference
- Ceapro announces adoption of CeaProve(TM) in global Glycemic Index study
- Ceapro announces 2005 second quarter financial results
- Ceapro Announces Granting of Stock Options
Later from Ceapro
- Ceapro announces Corporate Officer appointments
- Ceapro announces 2005 financial results
- Ceapro receives prestigious international award
- Ceapro announces 2006 first quarter financial results
- Ceapro Inc. - Annual General Meeting Webcast - June 1, 2006
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro